This subproject proposes a molecular cytogenetic approach to study marrow transplantation. To date, analyses of the genetic origin of hematopoietic cells post-transplant have been done primarily using cytogenetic techniques and have thus been limited to analysis of sex mismatched donor-recipient pairs. Here techniques for determining genetic origin using DNA restriction fragment length polymorphisms (RFLP) will be developed. RFLP analyses will be used to determine the frequency and causes of the leukemic transformation of donor cells posttransplant. RFLP analysis will also be used in conjunction with cytogenetic analysis to study the frequency and duration of mixed hematopoietic and lymphoid chimerism posttransplant and its relation to clinical outcome (i.e. relapse, GVHD, rejection, graft failure, etc.). Genetic differences between patients with CML in chronic phase, accelerated phase and blast crisis will also be analyzed to determine whether specific chromosomal abnormalities predispose to posttransplant relapse. Correlation between karyotypic changes and the frequency and timing of posttransplant relapse will be assessed using both cytogenetic and molecular genetic techniques. In addition, we will attempt to clone gene(s) which may be related to the clinical progression of CML and determine whether its expression can be correlated with posttransplant relapse.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-13
Application #
3819928
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764
Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Lee, Stephanie J; Onstad, Lynn; Chow, Eric J et al. (2018) Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103:1535-1541
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515

Showing the most recent 10 out of 1845 publications